| Glucagon-like peptide 1 in health and disease A Andersen, A Lund, FK Knop, T Vilsbøll Nature Reviews Endocrinology 14 (7), 390-403, 2018 | 429 | 2018 |
| Impaired regulation of the incretin effect in patients with type 2 diabetes JI Bagger, FK Knop, A Lund, H Vestergaard, JJ Holst, T Vilsbøll The Journal of Clinical Endocrinology & Metabolism 96 (3), 737-745, 2011 | 290 | 2011 |
| The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes A Lund, T Vilsbøll, JI Bagger, JJ Holst, FK Knop American Journal of Physiology-Endocrinology and Metabolism 300 (6), E1038-E1046, 2011 | 197 | 2011 |
| Regulation of glucagon secretion by incretins JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ... Diabetes, Obesity and Metabolism 13, 89-94, 2011 | 196 | 2011 |
| Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities A Lund, FK Knop, T Vilsbøll European journal of internal medicine 25 (5), 407-414, 2014 | 185 | 2014 |
| Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals MP Suppli, KTG Rigbolt, SS Veidal, S Heebøll, PL Eriksen, M Demant, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 316 (4 …, 2019 | 182 | 2019 |
| Evidence of extrapancreatic glucagon secretion in man A Lund, JI Bagger, NJ Wewer Albrechtsen, M Christensen, M Grøndahl, ... Diabetes 65 (3), 585-597, 2016 | 174 | 2016 |
| The role of glucagon in the pathophysiology and treatment of type 2 diabetes S Hædersdal, A Lund, FK Knop, T Vilsbøll Mayo Clinic Proceedings 93 (2), 217-239, 2018 | 153 | 2018 |
| Glucagon and type 2 diabetes: the return of the alpha cell A Lund, JI Bagger, M Christensen, FK Knop, T Vilsbøll Current diabetes reports 14, 1-7, 2014 | 150 | 2014 |
| Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ... Diabetologia 62, 665-675, 2019 | 102 | 2019 |
| Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals JI Bagger, FK Knop, A Lund, JJ Holst, T Vilsbøll Diabetologia 57, 1720-1725, 2014 | 84 | 2014 |
| Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia MB Christensen, A Lund, S Calanna, NR Jørgensen, JJ Holst, T Vilsbøll, ... The Journal of Clinical Endocrinology & Metabolism 103 (1), 288-294, 2018 | 78 | 2018 |
| Glucagon physiology I Rix, C Nexøe-Larsen, NC Bergmann, A Lund, FK Knop | 69 | 2015 |
| Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis MP Suppli, JI Bagger, A Lund, M Demant, G van Hall, C Strandberg, ... Diabetes 69 (6), 1090-1099, 2020 | 66 | 2020 |
| The effects of dual GLP-1/GIP receptor agonism on glucagon secretion—a review DS Mathiesen, JI Bagger, NC Bergmann, A Lund, MB Christensen, ... International journal of molecular sciences 20 (17), 4092, 2019 | 64 | 2019 |
| Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma NJW Albrechtsen, D Hornburg, R Albrechtsen, B Svendsen, S Toräng, ... EBioMedicine 7, 112-120, 2016 | 59 | 2016 |
| No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon … NC Bergmann, LS Gasbjerg, SM Heimbürger, LSL Krogh, F Dela, ... Diabetes Care 43 (3), 588-596, 2020 | 50 | 2020 |
| Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes NC Bergmann, A Lund, LS Gasbjerg, NR Jørgensen, L Jessen, ... The Journal of Clinical Endocrinology & Metabolism 104 (7), 2953-2960, 2019 | 48 | 2019 |
| Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ... The Lancet Diabetes & Endocrinology 8 (4), 313-324, 2020 | 47 | 2020 |
| Emerging GLP-1 receptor agonists A Lund, FK Knop, T Vilsbøll Expert opinion on emerging drugs 16 (4), 607-618, 2011 | 38 | 2011 |
